Tranexamic acid

Generic Name
Tranexamic acid
Brand Names
Cyklokapron, Lysteda
Drug Type
Small Molecule
Chemical Formula
C8H15NO2
CAS Number
1197-18-8
Unique Ingredient Identifier
6T84R30KC1
Background

Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication

Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleed...

Associated Conditions
Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
Associated Therapies
-

Assessment of Nebulized Tranexamic Acid in Functional Endoscopic Sinus Surgery Using Modena Bleeding Score

Early Phase 1
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-12-10
Last Posted Date
2024-12-10
Lead Sponsor
Assiut University
Target Recruit Count
90
Registration Number
NCT06725732

Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

First Posted Date
2024-10-26
Last Posted Date
2024-10-26
Lead Sponsor
Kristen Ban
Target Recruit Count
394
Registration Number
NCT06657924
Locations
🇺🇸

Cleveland Clinic Fairview Hospital, Cleveland, Ohio, United States

Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-10-16
Last Posted Date
2024-10-16
Lead Sponsor
University of Florida
Target Recruit Count
32
Registration Number
NCT06644079

Effect of TXA on Blood Loss in Reverse Total Shoulder Arthroplasty

First Posted Date
2024-10-11
Last Posted Date
2024-10-11
Lead Sponsor
University of Kansas Medical Center
Registration Number
NCT06638749
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Extended Oral Tranexamic Acid After Total Knee Arthroplasty

First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
Campbell Clinic
Target Recruit Count
120
Registration Number
NCT06618820
Locations
🇺🇸

Campbell Clinic, Germantown, Tennessee, United States

Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Not Applicable
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-09-19
Last Posted Date
2024-09-19
Lead Sponsor
University of Manitoba
Target Recruit Count
75
Registration Number
NCT06599762

Tranexamic Acid Versus Dexmedetomidine for Improving Surgical Field Quality During Spine Surgeries

First Posted Date
2024-09-09
Last Posted Date
2024-09-09
Lead Sponsor
Zagazig University
Target Recruit Count
78
Registration Number
NCT06587620
Locations
🇪🇬

Faculty of medicine, zagazig university, Zagazig, Elsharqya, Egypt

🇪🇬

Zagazig University, Zagazig, Egypt

Effects of Oral Tranexamic Acid Following Total Knee Arthroplasty

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2024-06-28
Last Posted Date
2024-12-13
Lead Sponsor
Matthew Grosso, MD
Target Recruit Count
80
Registration Number
NCT06479161
Locations
🇺🇸

Trinity Health Of New England/CT Joint Replacement Institute, Hartford, Connecticut, United States

Comparison of Chitosan, Ankaferd and Tranexamic Acid in Dental Extraction in Liver Pre-Transplant Children

First Posted Date
2024-06-13
Last Posted Date
2024-10-18
Lead Sponsor
British University In Egypt
Target Recruit Count
39
Registration Number
NCT06457360
Locations
🇪🇬

British University in Egypt, Cairo, Egypt

© Copyright 2024. All Rights Reserved by MedPath